RxDoctor Payments DataLook up a doctor →

Carlos Fierro

General Practice · Kansas City, KSNPI 1235251331

Payments from drug & device makers

$69,328,494in general payments, 2019–2025

Across 13,395 payments — averaging $5175.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$49.1M
  • Janssen Research & Development, LLC$6.7M
  • GSK$6M
  • Emergent Biosolutions Inc.$2.3M
  • Bavarian Nordic A/s$1.6M
  • Biontech SE$1.1M
  • plus $2.4M from 8 others
$57,496in research payments, 2019–2025

Across 38 payments — averaging $1513.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$56K
  • GSK$1K

General payments by program year

19
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.11,645$49,124,954
Janssen Research & Development, LLC87$6,726,336
GSK268$6,034,131
Emergent Biosolutions Inc.1,076$2,342,550
Bavarian Nordic A/s14$1,648,043
Biontech SE66$1,074,602
Novavax Inc47$708,286
AstraZeneca6$559,219
Pfizer69$548,828
Regeneron4$248,000
Takeda Pharmaceuticals U.S.A., Inc.92$186,003
Johnson & Johnson19$112,895
Incyte Corporation1$14,534
Otsuka America Pharmaceutical, Inc.1$112

How this compares

$69,328,494 in reported general payments places this provider in the 95th percentile of 771 general practice providers in Kansas.

See all general practice providers in Kansas

Other general practice in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →